Cipla advanced 0.45% to Rs 445.15 after it announced the acquisition of nutrition products' portfolio from Wanbury.
The drug maker said that it has acquired 4 brands CPink, CDense, Productiv and Folinine to further strengthen its presence in women's health. It added that the nutraceutical products, to be sold under the 4 umbrella brands, would address various health needs for conditions arising due to nutritional deficiencies or insufficiencies.
This includes supplements such as multivitamins, multimineral and antioxidants for adolescent girls, pregnant and lactating women, women going through menopause and for male and female reproductive health.
As per (IQVIA MAT Dec'19), the above molecules previously commercialized by Wanbury have a market size of Rs 3,100 crore in India with sales value of Rs 59.6 crore.
Cipla is a global pharmaceutical company.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)